SCHEMBL3545052

SCHEMBL3545052

C/C=C/[C@H](C)COCc1ccc(OC)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
IDO1 P14902 3/20 0.44
AGXT P21549 2/20 0.44
SLC6A4 P31645 1/20 0.42
TBXAS1 P24557 2/20 0.42
APP P05067 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
ALOX12 P18054 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAOB P27338 1/20 0.39
MMP2 P08253 1/20 0.38
MMP3 P08254 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3545056 1.00 CA1 (0.53) CA1CA2IDO1AGXTSLC6A4
SCHEMBL13547256 1.00 CA1 (0.53) CA1CA2IDO1AGXTSLC6A4
SCHEMBL7189854 0.83 CA1 (0.49) CA1CA2IDO1AGXTSLC6A4
SCHEMBL7195232 0.83 CA1 (0.49) CA1CA2IDO1AGXTSLC6A4
SCHEMBL7195228 0.83 CA1 (0.49) CA1CA2IDO1AGXTSLC6A4
SCHEMBL7189861 0.83 CA1 (0.49) CA1CA2IDO1AGXTSLC6A4
SCHEMBL7190391 0.82 CA1 (0.54) CA1CA2IDO1AGXTSLC6A4
SCHEMBL5229745 0.82 CA1 (0.54) CA1CA2IDO1AGXTSLC6A4
SCHEMBL3557233 0.82 CA1 (0.54) CA1CA2IDO1AGXTSLC6A4
SCHEMBL15314133 0.80 SLC6A4 (0.56) IDO1AGXTSLC6A4L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645782-B2 Thia-epothilone derivatives for the treatment of cancer Richter, Wolfgang (DE) 2010-01-12 US disclosed
US-7553859-B2 Macrocycles for the treatment of cancer Richter, Wolfgang (DE) 2009-06-30 US disclosed
US-20060128966-A1 Thia-epothilone derivatives for the treatment of cancer MORPHONCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2006-06-15 US disclosed
US-20060004065-A1 Novel macrocycles for the treatment of cancer WOLFGANG RICHTER (DE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128966-A1 Thia-epothilone derivatives for the treatment of cancer TTPA, THPO, TERT CA1 4725/4885CA2 4710/4885IDO1 2992/4885
US-20060004065-A1 Novel macrocycles for the treatment of cancer CCNI, CCNB1, CCNC CA1 3681/4885CA2 3910/4885IDO1 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.